Meridiano

Add Article

No Image Available

Article Details

Title

Article: China and Hong Kong should relax biotech listing rules, venture capitalist says

Impact Score

5 / 10

AI Summary (Processed Content)

A venture capitalist is advocating for China and Hong Kong to relax listing rules for biotech companies and lower takeover thresholds for listed firms. This call aims to capitalize on renewed foreign investment interest in the healthcare and biopharmaceutical sectors.

The recommendation highlights regulatory bottlenecks, particularly at the China Securities Regulatory Commission, which are slowing down the pipeline for new initial public offerings. Hong Kong's role as a key capital center for AI and healthcare is noted as a foundation for this potential growth.

The main topics covered are financial regulation, biotechnology and healthcare investment, and the stock markets in Hong Kong and mainland China.

Original URL

https://www.scmp.com/business/banking-finance/article/3345589/china-and-hong-kong-should-relax-biotech-listing-rules-venture-capitalist-says?utm_source=rss_feed

Source Feed

Tech - South China Morning Post

Published Date

2026-03-05 10:59

Fetched Date

2026-03-05 08:30

Processed Date

2026-03-05 08:31

Embedding Status

Present

Cluster ID

Not Clustered

Raw Extracted Content

China and Hong Kong should relax biotech listing rules, venture capitalist says
Foreign investors are returning to China’s healthcare sector, but IPO bottlenecks and takeover rules could deter deals, VC Nisa Leung says
Mainland China and Hong Kong should ease listing rules for biotechnology companies and lower takeover thresholds for listed firms to capitalise on renewed foreign interest in the healthcare sector, venture capitalist Nisa Leung said.
“Besides artificial intelligence, Premier Li Qiang also highlighted biomedicine in the ‘two sessions’ annual government work report,” said Leung, a former managing partner at Qiming Venture Partners, speaking in a sideline interview during China’s annual meetings of the National Committee of the Chinese People’s Political Consultative Conference (CPPCC) and the National People’s Congress (NPC).
“We are paying attention to medical insurance and commercial insurance, but at the same time we are also looking at how biopharmaceutical companies can expand overseas,” said Leung, who is a member of the CPPCC.
“Hong Kong has also become a very important [capital] centre for AI and healthcare,” she added, citing the successful listing of Insilico Medicine last year in Hong Kong, which she described as a milestone for the sector.
The AI-driven drug discovery company raised HK$2.28 billion (US$290 million) in the share sale. However, she noted that regulatory bottlenecks were slowing the pipeline of new listings.
“Many are stuck in the approval process at the China Securities Regulatory Commission [CSRC],” she said.